Premium
Single and combined effects of plant‐derived and synthetic cannabinoids on cognition and cannabinoid‐associated withdrawal signs in mice
Author(s) -
Myers Alyssa M,
Siegele Patrick B,
Foss Jeffrey D,
Tuma Ronald F,
Ward Sara Jane
Publication year - 2019
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14147
Subject(s) - cannabidiol , cannabinoid receptor , cannabinoid , pharmacology , rimonabant , antagonist , agonist , tetrahydrocannabinol , medicine , cannabinoid receptor antagonist , partial agonist , receptor antagonist , cannabinoid receptor type 2 , receptor , cannabis , psychiatry
It has been suggested that the non-euphorogenic phytocannabinoid cannabidiol (CBD) can ameliorate adverse effects of Δ 9 -tetrahydrocannabinol (THC). We determined whether CBD ameliorates cognitive deficits and withdrawal signs induced by cannabinoid CB 1 /CB 2 receptor agonists or produces these pharmacological effects on its own.